Clinical Application of the HCM-AF Risk Score in the Prediction of Clinical Outcomes of Polish Patients with Hypertrophic Cardiomyopathy
The recently introduced HCM-AF Risk Calculator allows the prognosis of atrial fibrillation (AF) occurrence in hypertrophic cardiomyopathy (HCM) patients. The aim of this study was to assess the clinical application of the HCM-AF Risk Score in the prediction of the clinical outcomes of Polish patient...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-07-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/12/13/4484 |
| _version_ | 1797591428330684416 |
|---|---|
| author | Maria Stec Agata Suleja Daniel Gondko Wiktoria Kuczmik Jakub Roman Dominika Dziadosz Krzysztof Szydło Katarzyna Mizia-Stec |
| author_facet | Maria Stec Agata Suleja Daniel Gondko Wiktoria Kuczmik Jakub Roman Dominika Dziadosz Krzysztof Szydło Katarzyna Mizia-Stec |
| author_sort | Maria Stec |
| collection | DOAJ |
| description | The recently introduced HCM-AF Risk Calculator allows the prognosis of atrial fibrillation (AF) occurrence in hypertrophic cardiomyopathy (HCM) patients. The aim of this study was to assess the clinical application of the HCM-AF Risk Score in the prediction of the clinical outcomes of Polish patients. The study included 92 patients (50.0% female, median age 55 years), with a baseline sinus rhythm diagnosed between 2013 and 2018. The analysis involved the incidence of clinical characteristics and outcomes, total mortality, rehospitalisation, and the course of heart failure (HF). According to the HCM-AF Risk Score, the HCM population was stratified into three subgroups, with a low (13/14.2%), intermediate (30/32.6%), and high risk of AF (49/53.2%). Subgroups differed significantly: the high-risk subgroup was older, had a higher body mass index (BMI), and more advanced signs of left ventricular (LV) hypertrophy and left atrium (LA) dilatation. The registered AF incidence was 31.5% and 43.5% in the 2- and 5-year follow-ups, and it was significantly higher than in the HCM-AF Risk Score population, which had 4.6% in the 2-year follow-up, and 10.7% in the 5-year follow-up. In the whole population, the AF incidence in both the 2- and 5-year follow-ups revealed a strong correlation with the HCM-AF Risk Score (r = 0.442, <i>p</i> < 0.001; r = 0.346, <i>p</i> < 0.001, respectively). The clinical outcomes differed among the subgroups: the total mortality was 15.4% vs. 20.0% vs. 42.9% (<i>p</i> < 0.05); rehospitalisation was 23.1% vs. 53.3% vs. 71.4% (<i>p</i> < 0.05). The highest HF progression was in the high-risk subgroup (36.7%). Regardless of the high results of the HCM-Risk Score in Polish patients, the score underestimates the real-life high level of AF incidence. The HCM-AF Risk Score seems to be useful in the prediction of the general clinical outcomes in HCM patients. |
| first_indexed | 2024-03-11T01:37:16Z |
| format | Article |
| id | doaj.art-8f4bd27182b0490bbc965ba7a851802d |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-11T01:37:16Z |
| publishDate | 2023-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-8f4bd27182b0490bbc965ba7a851802d2023-11-18T16:54:32ZengMDPI AGJournal of Clinical Medicine2077-03832023-07-011213448410.3390/jcm12134484Clinical Application of the HCM-AF Risk Score in the Prediction of Clinical Outcomes of Polish Patients with Hypertrophic CardiomyopathyMaria Stec0Agata Suleja1Daniel Gondko2Wiktoria Kuczmik3Jakub Roman4Dominika Dziadosz5Krzysztof Szydło6Katarzyna Mizia-Stec7Students’ Research Group of the 1st Department of Cardiology, Medical University of Silesia, 47 Ziołowa St., 40-635 Katowice, PolandStudents’ Research Group of the 1st Department of Cardiology, Medical University of Silesia, 47 Ziołowa St., 40-635 Katowice, PolandStudents’ Research Group of the 1st Department of Cardiology, Medical University of Silesia, 47 Ziołowa St., 40-635 Katowice, PolandStudents’ Research Group of the 1st Department of Cardiology, Medical University of Silesia, 47 Ziołowa St., 40-635 Katowice, PolandStudents’ Research Group of the 1st Department of Cardiology, Medical University of Silesia, 47 Ziołowa St., 40-635 Katowice, Poland1st Department of Cardiology, Medical University of Silesia, European Reference Network of Heart Diseases (ERN GUARD-HEART), 47 Ziołowa St., 40-635 Katowice, Poland1st Department of Cardiology, Medical University of Silesia, European Reference Network of Heart Diseases (ERN GUARD-HEART), 47 Ziołowa St., 40-635 Katowice, Poland1st Department of Cardiology, Medical University of Silesia, European Reference Network of Heart Diseases (ERN GUARD-HEART), 47 Ziołowa St., 40-635 Katowice, PolandThe recently introduced HCM-AF Risk Calculator allows the prognosis of atrial fibrillation (AF) occurrence in hypertrophic cardiomyopathy (HCM) patients. The aim of this study was to assess the clinical application of the HCM-AF Risk Score in the prediction of the clinical outcomes of Polish patients. The study included 92 patients (50.0% female, median age 55 years), with a baseline sinus rhythm diagnosed between 2013 and 2018. The analysis involved the incidence of clinical characteristics and outcomes, total mortality, rehospitalisation, and the course of heart failure (HF). According to the HCM-AF Risk Score, the HCM population was stratified into three subgroups, with a low (13/14.2%), intermediate (30/32.6%), and high risk of AF (49/53.2%). Subgroups differed significantly: the high-risk subgroup was older, had a higher body mass index (BMI), and more advanced signs of left ventricular (LV) hypertrophy and left atrium (LA) dilatation. The registered AF incidence was 31.5% and 43.5% in the 2- and 5-year follow-ups, and it was significantly higher than in the HCM-AF Risk Score population, which had 4.6% in the 2-year follow-up, and 10.7% in the 5-year follow-up. In the whole population, the AF incidence in both the 2- and 5-year follow-ups revealed a strong correlation with the HCM-AF Risk Score (r = 0.442, <i>p</i> < 0.001; r = 0.346, <i>p</i> < 0.001, respectively). The clinical outcomes differed among the subgroups: the total mortality was 15.4% vs. 20.0% vs. 42.9% (<i>p</i> < 0.05); rehospitalisation was 23.1% vs. 53.3% vs. 71.4% (<i>p</i> < 0.05). The highest HF progression was in the high-risk subgroup (36.7%). Regardless of the high results of the HCM-Risk Score in Polish patients, the score underestimates the real-life high level of AF incidence. The HCM-AF Risk Score seems to be useful in the prediction of the general clinical outcomes in HCM patients.https://www.mdpi.com/2077-0383/12/13/4484hypertrophic cardiomyopathyatrial fibrillationHCM-AF Risk Score |
| spellingShingle | Maria Stec Agata Suleja Daniel Gondko Wiktoria Kuczmik Jakub Roman Dominika Dziadosz Krzysztof Szydło Katarzyna Mizia-Stec Clinical Application of the HCM-AF Risk Score in the Prediction of Clinical Outcomes of Polish Patients with Hypertrophic Cardiomyopathy Journal of Clinical Medicine hypertrophic cardiomyopathy atrial fibrillation HCM-AF Risk Score |
| title | Clinical Application of the HCM-AF Risk Score in the Prediction of Clinical Outcomes of Polish Patients with Hypertrophic Cardiomyopathy |
| title_full | Clinical Application of the HCM-AF Risk Score in the Prediction of Clinical Outcomes of Polish Patients with Hypertrophic Cardiomyopathy |
| title_fullStr | Clinical Application of the HCM-AF Risk Score in the Prediction of Clinical Outcomes of Polish Patients with Hypertrophic Cardiomyopathy |
| title_full_unstemmed | Clinical Application of the HCM-AF Risk Score in the Prediction of Clinical Outcomes of Polish Patients with Hypertrophic Cardiomyopathy |
| title_short | Clinical Application of the HCM-AF Risk Score in the Prediction of Clinical Outcomes of Polish Patients with Hypertrophic Cardiomyopathy |
| title_sort | clinical application of the hcm af risk score in the prediction of clinical outcomes of polish patients with hypertrophic cardiomyopathy |
| topic | hypertrophic cardiomyopathy atrial fibrillation HCM-AF Risk Score |
| url | https://www.mdpi.com/2077-0383/12/13/4484 |
| work_keys_str_mv | AT mariastec clinicalapplicationofthehcmafriskscoreinthepredictionofclinicaloutcomesofpolishpatientswithhypertrophiccardiomyopathy AT agatasuleja clinicalapplicationofthehcmafriskscoreinthepredictionofclinicaloutcomesofpolishpatientswithhypertrophiccardiomyopathy AT danielgondko clinicalapplicationofthehcmafriskscoreinthepredictionofclinicaloutcomesofpolishpatientswithhypertrophiccardiomyopathy AT wiktoriakuczmik clinicalapplicationofthehcmafriskscoreinthepredictionofclinicaloutcomesofpolishpatientswithhypertrophiccardiomyopathy AT jakubroman clinicalapplicationofthehcmafriskscoreinthepredictionofclinicaloutcomesofpolishpatientswithhypertrophiccardiomyopathy AT dominikadziadosz clinicalapplicationofthehcmafriskscoreinthepredictionofclinicaloutcomesofpolishpatientswithhypertrophiccardiomyopathy AT krzysztofszydło clinicalapplicationofthehcmafriskscoreinthepredictionofclinicaloutcomesofpolishpatientswithhypertrophiccardiomyopathy AT katarzynamiziastec clinicalapplicationofthehcmafriskscoreinthepredictionofclinicaloutcomesofpolishpatientswithhypertrophiccardiomyopathy |